HC Wainwright began coverage on shares of Bright Minds Biosciences (NASDAQ:DRUG - Free Report) in a report released on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a $85.00 target price on the stock.
A number of other analysts also recently weighed in on DRUG. Baird R W upgraded Bright Minds Biosciences to a "strong-buy" rating in a research report on Monday, November 25th. Robert W. Baird started coverage on Bright Minds Biosciences in a research note on Monday, November 25th. They issued an "outperform" rating and a $75.00 price target for the company.
Get Our Latest Stock Report on Bright Minds Biosciences
Bright Minds Biosciences Stock Down 5.2 %
Shares of Bright Minds Biosciences stock traded down $2.15 during trading on Friday, reaching $38.89. The company's stock had a trading volume of 48,725 shares, compared to its average volume of 72,071. Bright Minds Biosciences has a 52 week low of $0.93 and a 52 week high of $79.02. The firm has a market cap of $172.44 million, a PE ratio of -57.19 and a beta of -6.52. The business's 50-day moving average price is $40.68 and its 200-day moving average price is $18.68.
Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last posted its quarterly earnings data on Monday, December 30th. The company reported ($0.12) earnings per share (EPS) for the quarter.
Insiders Place Their Bets
In related news, major shareholder Cormorant Asset Management, Lp purchased 372,591 shares of the firm's stock in a transaction that occurred on Tuesday, October 15th. The shares were bought at an average cost of $5.53 per share, with a total value of $2,060,428.23. Following the acquisition, the insider now owns 825,000 shares of the company's stock, valued at $4,562,250. This trade represents a 82.36 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 42.66% of the company's stock.
About Bright Minds Biosciences
(
Get Free Report)
Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.
See Also
Before you consider Bright Minds Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bright Minds Biosciences wasn't on the list.
While Bright Minds Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
